

# Investor Relations Brief

2

2025

February



# Business Division Progress Report

## CosmeRNA

The CosmeRNA division has launched its Amazon USA store and official U.S. shopping mall to enhance purchasing convenience for American customers. As part of its market expansion, the company conducted an in-depth interview with a special correspondent from the Chicago Korea Times, prioritizing the Korean-American community for its initial outreach. During the interview, CosmeRNA highlighted its innovative technology, developed through 33 years of expertise and five patented genetic technologies—the first of their kind to be commercialized in Korea. With proven effectiveness and high safety standards, CosmeRNA is pioneering a new era in cosmetic solutions.

Meanwhile, CosmeRNA's key ingredient has received patent approval in Japan, following previous registrations in Korea, China, Australia, and Russia. As patents continue to be granted in major global markets, CosmeRNA is securing a long-term exclusive business model based on substance patents, ensuring market protection until the early 2040s. By leveraging this strong patent foundation, CosmeRNA is establishing itself as a premium, high-value cosmetic brand and laying the groundwork for growth into a globally recognized company in major developed countries.

To further its global expansion, CosmeRNA has signed a joint development agreement with Cutaneon, a German hair loss research company founded by world-renowned hair loss expert Dr. Ralf Paus. Unlike conventional treatments that primarily target androgenetic alopecia (AGA), this collaboration aims to develop next-generation functional cosmetics that address hair loss caused by various other key mechanisms. The partnership will focus on promoting scalp health and reducing hair loss, broadening the scope of CosmeRNA's hair care solutions.

Additionally, CosmeRNA participated in IMCAS Paris 2025, held from January 30 to February 1, where it introduced its product to medical professionals. Strategic and effective marketing efforts at the event significantly increased brand awareness among attending physicians, leading to highly positive feedback on the product's potential and effectiveness.

## AceBiome

AceBiome saw strong sales during the Lunar New Year with successful promotions via home shopping and online channels. It also strengthened customer engagement through product experience events at Costco.

At the 2025 Korea First Brand Awards, BNRTthin and BNRTQueen won first place for the third consecutive year in the "Dietary Probiotics" and "Menopausal Probiotics" categories, reaffirming AceBiome's market leadership.

Globally, the company is expanding brand awareness through influencer marketing on Douyin, China's top short-form video platform. BNRTthin also won the top award in the "Dietary Probiotics" category at a People's Daily Online consumer evaluation, boosting its growth in the Greater China market.

## siRNAgen

siRNAgen has finalized the target condition for its Phase 1b trial, selecting the fastest route to efficacy validation. Expanding beyond IV administration to subcutaneous injection, the company aims to treat chronic fibrotic diseases like obesity and kidney disease. Preclinical animal studies are underway for an IND application.


The trial will assess SRN-001's repeated-dose toxicity and pharmacokinetics, aiming to confirm its superior safety and efficacy over existing siRNA drugs—a key step toward global partnerships and commercialization.

Given frequent delays in IPF trials due to patient recruitment issues, siRNAgen has identified new fibrosis-related indications with input from U.S. and Korean clinical experts. The company is collaborating with a top nephrology professor in Korea to finalize an animal study protocol for additional efficacy data supporting the IND submission.



## CosmeRNA Targets the US Market by Amazon and Online Store

Earlier this year, BIONEER took a major step in penetrating the U.S. market by launching on Amazon USA. As the world's largest online marketplace with over 300 million active users, Amazon USA provides a strategic platform for BIONEER to enhance consumer accessibility to CosmeRNA across the United States.



**amazon** Deliver to Republic of Korea All Search Amazon Q EN Hello, sign in Account & Lists Returns & Orders Cart

Get free international delivery

Today's Deals Customer Service Registry Gift Cards Sell

**CLINICALLY VISIBLE RESULTS IN 16 WEEKS\***

\*Clinical test with weekly treatment - 86% of participants showed positive results at the first checkpoint after 16 weeks and 91% after 24 weeks. Results may vary among individuals.

REF) Weekly treatment with SAMRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep. 2022 Jan 31;12(1):1607. CosmeRNA

- Once a week application**  
Just once a week is all it takes. In a clinical study, 91% of users who applied CosmeRNA weekly saw improvements in hair density after 4-6 months.
- Certified Skin Safety**  
CosmeRNA received an "Excellent" 5-Star Seal by Dermatist in Germany.
- Topical Care for Thinning Hair**  
Our clinical trials showed no adverse reactions, ensuring that CosmeRNA can be confidently used to improve thinning hair through its targeted action within the hair follicles.
- For Men&Women**  
CosmeRNA is effective for both men and women, making it an ideal solution for those experiencing hair thinning and shedding along the dotted or crown.

Additionally, we launched our official online store to enhance accessibility and convenience. Designed for a seamless user experience, it features Before & After photos to showcase CosmeRNA's effectiveness and build trust.



**CosmeRNA** Login Q

Home / CosmeRNA Hair Revitalizing Tonic 2ml Home Shop Contact Us

## Real Results\*, Real Reviews



Before (July 2023)



After (November 2024)



Before



After 3 months

\* Results may vary among individuals.



## CosmeRNA Participates in IMCAS Paris 2025 Conference

BIONEER's SAMiRNA™-based topical scalp cosmetic, CosmeRNA, garnered attention as an innovative beauty solution at this conference, confirming its strong potential for adoption in the European medical market. In particular, by strengthening marketing efforts in Europe and the Middle East, the product received positive feedback from local medical professionals and industry experts.







Additionally, we discussed the exclusive distributor agreement negotiations with our partner in Saudi Arabia. We also received collaboration proposals aimed at global market expansion, including research cooperation suggestions from specialists in Brazil, India, and the Middle East.

